Frequent deletion of 3p21.1 region carrying semaphorin 3G and aberrant expression of the genes participating in semaphorin signaling in the epithelioid type of malignant mesothelioma cells

  • Authors:
    • Yoshie Yoshikawa
    • Ayuko Sato
    • Tohru Tsujimura
    • Tomonori Morinaga
    • Kazuya Fukuoka
    • Shusai Yamada
    • Aki Murakami
    • Nobuyuki Kondo
    • Seiji Matsumoto
    • Yoshitomo Okumura
    • Fumihiro Tanaka
    • Seiki Hasegawa
    • Tomoko Hashimoto-Tamaoki
    • Takashi Nakano
  • View Affiliations

  • Published online on: August 12, 2011     https://doi.org/10.3892/ijo.2011.1158
  • Pages: 1365-1374
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Array-based comparative genomic hybridization analysis was performed on 21 malignant mesothelioma (MM) samples (16 primary cell cultures and 5 cell lines) and two reactive mesothelial hyperplasia (RM) primary cell cultures. The RM samples did not have any genomic losses or gains. In MM samples, deletions in 1p, 3p21, 4q, 9p21, 16p13 and 22q were detected frequently. We focused on 3p21 because this deletion was specific to the epithelioid type. Especially, a deletion in 3p21.1 region carrying seven genes including SEMA3G was found in 52% of MM samples (11 of 14 epithelioid samples). The allele loss of 3p21.1 might be a good marker for the epithelioid MM. A homozygous deletion in this region was detected in two MM primary cell cultures. A heterozygous deletion detected in nine samples contained the 3p21.1 region and 3p21.31 one carrying the candidate tumor suppressor genes such as semaphorin 3F (SEMA3F), SEMA3B and Ras association (RalGDS/AF-6) domain family member 1 (RASSF1A). SEMA3B, 3F and 3G are class 3 semaphorins and inhibit growth by competing with vascular endothelial growth factor (VEGF) through binding to neuropilin. All MM samples downregulated the expression of more than one gene for SEMA3B, 3F and 3G when compared with Met5a, a normal pleura-derived cell line. Moreover, in 12 of 14 epithelioid MM samples the expression level of SEMA3A was lower than that in Met5a and the two RM samples. An augmented expression of VEGFA was detected in half of the MM samples. The expression ratio of VEGFA/SEMA3A was significantly higher in the epithelioid MMs than in Met5a, RMs and the non-epithelioid MMs. Our data suggest that the downregulated expression of SEMA3A and several SEMA3s results in a loss of inhibitory activities in tumor angiogenesis and tumor growth of VEGFA; therefore, it may play an important role on the pathogenesis of the epithelioid type of MM.

Related Articles

Journal Cover

December 2011
Volume 39 Issue 6

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Yoshikawa, Y., Sato, A., Tsujimura, T., Morinaga, T., Fukuoka, K., Yamada, S. ... Nakano, T. (2011). Frequent deletion of 3p21.1 region carrying semaphorin 3G and aberrant expression of the genes participating in semaphorin signaling in the epithelioid type of malignant mesothelioma cells. International Journal of Oncology, 39, 1365-1374. https://doi.org/10.3892/ijo.2011.1158
MLA
Yoshikawa, Y., Sato, A., Tsujimura, T., Morinaga, T., Fukuoka, K., Yamada, S., Murakami, A., Kondo, N., Matsumoto, S., Okumura, Y., Tanaka, F., Hasegawa, S., Hashimoto-Tamaoki, T., Nakano, T."Frequent deletion of 3p21.1 region carrying semaphorin 3G and aberrant expression of the genes participating in semaphorin signaling in the epithelioid type of malignant mesothelioma cells". International Journal of Oncology 39.6 (2011): 1365-1374.
Chicago
Yoshikawa, Y., Sato, A., Tsujimura, T., Morinaga, T., Fukuoka, K., Yamada, S., Murakami, A., Kondo, N., Matsumoto, S., Okumura, Y., Tanaka, F., Hasegawa, S., Hashimoto-Tamaoki, T., Nakano, T."Frequent deletion of 3p21.1 region carrying semaphorin 3G and aberrant expression of the genes participating in semaphorin signaling in the epithelioid type of malignant mesothelioma cells". International Journal of Oncology 39, no. 6 (2011): 1365-1374. https://doi.org/10.3892/ijo.2011.1158